Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.43 |
| ▸ | INSR | P06213 | 7/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.34 |
| ▸ | MET | P08581 | 3/20 | 0.33 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31701872 | 1.00 | CRBN (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL30661469 | 0.92 | DDB1 (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL26621524 | 0.92 | DDB1 (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL30661561 | 0.92 | DDB1 (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL26621701 | 0.92 | DDB1 (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL30661577 | 0.92 | DDB1 (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL26621517 | 0.92 | DDB1 (0.43) | CRBNDDB1INSRALKMET | |
| SCHEMBL30661504 | 0.92 | DDB1 (0.40) | CRBNDDB1INSRALKMET | |
| SCHEMBL30661472 | 0.92 | DDB1 (0.36) | CRBNDDB1INSRALKMET | |
| SCHEMBL26621420 | 0.92 | DDB1 (0.36) | CRBNDDB1INSRALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | CRBN 91/4885DDB1 280/4885INSR 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.